Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=52)			rhNGF 20 µg/ml (N=52)			Vehicle Control (N=52)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Any Adverse Events	54	23	(44.2%)	51	27	(51.9%)	50	20	(38.5%)	155	70	(44.9%)
Eye disorders	29	17	(32.7%)	21	13	(25.0%)	30	16	(30.8%)	80	46	(29.5%)
Eye pain	2	2	(3.8%)	5	5	(9.6%)	6	4	(7.7%)	13	11	(7.1%)
Visual acuity reduced	2	2	(3.8%)	3	3	(5.8%)	2	2	(3.8%)	7	7	(4.5%)
Blepharitis	2	2	(3.8%)	1	1	(1.9%)	1	1	(1.9%)	4	4	(2.6%)
Eye pruritus	2	2	(3.8%)	1	1	(1.9%)	1	1	(1.9%)	4	4	(2.6%)
Lacrimation increased	3	3	(5.8%)	0	0		1	1	(1.9%)	4	4	(2.6%)
Conjunctival hyperaemia	2	2	(3.8%)	0	0		1	1	(1.9%)	3	3	(1.9%)
Dry eye	1	1	(1.9%)	0	0		2	2	(3.8%)	3	3	(1.9%)
Eye irritation	2	2	(3.8%)	0	0		1	1	(1.9%)	3	3	(1.9%)
Photophobia	2	2	(3.8%)	0	0		1	1	(1.9%)	3	3	(1.9%)
Vision blurred	1	1	(1.9%)	0	0		2	2	(3.8%)	3	3	(1.9%)
Corneal deposits	0	0		3	2	(3.8%)	0	0		3	2	(1.3%)
Corneal epithelium defect	1	1	(1.9%)	0	0		2	1	(1.9%)	3	2	(1.3%)
Corneal neovascularisation	0	0		1	1	(1.9%)	1	1	(1.9%)	2	2	(1.3%)
Eye discharge	1	1	(1.9%)	1	1	(1.9%)	0	0		2	2	(1.3%)
Keratitis	0	0		2	2	(3.8%)	0	0		2	2	(1.3%)
Ocular hyperaemia	0	0		1	1	(1.9%)	1	1	(1.9%)	2	2	(1.3%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=52)			rhNGF 20 µg/ml (N=52)			Vehicle Control (N=52)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Eye disorders												
Abnormal sensation in eye	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Asthenopia	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Conjunctival haemorrhage	0	0		0	0		2	1	(1.9%)	2	1	(0.6%)
Corneal endotheliitis	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Corneal oedema	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Corneal opacity	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Eye allergy	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Eye inflammation	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Eyelid oedema	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Eyelid pain	2	1	(1.9%)	0	0		0	0		2	1	(0.6%)
Eyelid ptosis	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Foreign body sensation in eyes	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Lagophthalmos	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Macular fibrosis	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Ocular discomfort	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Posterior capsule opacification	2	1	(1.9%)	0	0		0	0		2	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=52)			rhNGF 20 µg/ml (N=52)			Vehicle Control (N=52)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Infections and infestations	6	6	(11.5%)	9	7	(13.5%)	2	2	(3.8%)	17	15	(9.6%)
Nasopharyngitis	1	1	(1.9%)	3	2	(3.8%)	1	1	(1.9%)	5	4	(2.6%)
Gastroenteritis	1	1	(1.9%)	0	0		1	1	(1.9%)	2	2	(1.3%)
Conjunctivitis bacterial	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Corneal abscess	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Corneal infection	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Diverticulitis	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Influenza	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Lower respiratory tract infection	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Oral herpes	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Staphylococcal infection	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Upper respiratory tract infection	0	0		2	1	(1.9%)	0	0		2	1	(0.6%)
General disorders and administration site conditions	4	4	(7.7%)	2	2	(3.8%)	7	7	(13.5%)	13	13	(8.3%)
Disease progression	2	2	(3.8%)	2	2	(3.8%)	6	6	(11.5%)	10	10	(6.4%)
Fatigue	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Instillation site pain	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Pyrexia	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=52)			rhNGF 20 µg/ml (N=52)			Vehicle Control (N=52)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Nervous system disorders	4	4	(7.7%)	2	2	(3.8%)	2	2	(3.8%)	8	8	(5.1%)
Headache	2	2	(3.8%)	2	2	(3.8%)	2	2	(3.8%)	6	6	(3.8%)
Neuralgia	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Trigeminal neuralgia	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Injury, poisoning and procedural complications	2	2	(3.8%)	0	0		3	2	(3.8%)	5	4	(2.6%)
Fall	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Laceration	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Periorbital haematoma	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Suture related complication	0	0		0	0		2	1	(1.9%)	2	1	(0.6%)
Investigations	1	1	(1.9%)	2	2	(3.8%)	1	1	(1.9%)	4	4	(2.6%)
Intraocular pressure increased	1	1	(1.9%)	1	1	(1.9%)	0	0		2	2	(1.3%)
Alanine aminotransferase increased	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Blood pressure increased	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Metabolism and nutrition disorders	1	1	(1.9%)	3	2	(3.8%)	1	1	(1.9%)	5	4	(2.6%)
Folate deficiency	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Hypercholesterolaemia	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Hypertriglyceridaemia	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=52)			rhNGF 20 µg/ml (N=52)			Vehicle Control (N=52)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Metabolism and nutrition disorders												
Iron deficiency	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Vitamin B12 deficiency	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Gastrointestinal disorders	2	2	(3.8%)	1	1	(1.9%)	0	0		3	3	(1.9%)
Nausea	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Toothache	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Vomiting	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Immune system disorders	0	0		3	2	(3.8%)	1	1	(1.9%)	4	3	(1.9%)
Corneal graft rejection	0	0		3	2	(3.8%)	1	1	(1.9%)	4	3	(1.9%)
Vascular disorders	1	1	(1.9%)	2	2	(3.8%)	0	0		3	3	(1.9%)
Aortic dissection	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Hypertension	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Venous thrombosis	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=52)			rhNGF 20 µg/ml (N=52)			Vehicle Control (N=52)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Blood and lymphatic system disorders	0	0		2	2	(3.8%)	0	0		2	2	(1.3%)
Anaemia	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Neutropenia	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Cardiac disorders	1	1	(1.9%)	1	1	(1.9%)	0	0		2	2	(1.3%)
Arrhythmia	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Myocardial infarction	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Ear and labyrinth disorders	1	1	(1.9%)	1	1	(1.9%)	0	0		2	2	(1.3%)
Ear pain	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)
Vertigo	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	1	1	(1.9%)	1	1	(1.9%)	0	0		2	2	(1.3%)
Malignant neoplasm progression	1	1	(1.9%)	1	1	(1.9%)	0	0		2	2	(1.3%)
Respiratory, thoracic and mediastinal disorders	1	1	(1.9%)	0	0		1	1	(1.9%)	2	2	(1.3%)
Dysphonia	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Respiratory distress	1	1	(1.9%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Controlled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=52)			rhNGF 20 µg/ml (N=52)			Vehicle Control (N=52)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Renal and urinary disorders	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Renal colic	0	0		1	1	(1.9%)	0	0		1	1	(0.6%)
Skin and subcutaneous tissue disorders	0	0		0	0		2	1	(1.9%)	2	1	(0.6%)
Dry skin	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)
Onychoclasis	0	0		0	0		1	1	(1.9%)	1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Uncontrolled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=10)			rhNGF 20 µg/ml (N=13)			Total (N=23)		
	N*	n	%	N*	n	%	N*	n	%
Any Adverse Events	6	4	(40.0%)	16	7	(53.8%)	22	11	(47.8%)
Eye disorders	2	2	(20.0%)	13	6	(46.2%)	15	8	(34.8%)
Blepharitis	0	0		3	3	(23.1%)	3	3	(13.0%)
Ulcerative keratitis	1	1	(10.0%)	1	1	(7.7%)	2	2	(8.7%)
Visual acuity reduced	0	0		2	2	(15.4%)	2	2	(8.7%)
Conjunctival hyperaemia	0	0		1	1	(7.7%)	1	1	(4.3%)
Erythema of eyelid	0	0		1	1	(7.7%)	1	1	(4.3%)
Eye discharge	0	0		1	1	(7.7%)	1	1	(4.3%)
Eye irritation	0	0		1	1	(7.7%)	1	1	(4.3%)
Eye pain	0	0		1	1	(7.7%)	1	1	(4.3%)
Eyelid oedema	0	0		2	1	(7.7%)	2	1	(4.3%)
Vision blurred	1	1	(10.0%)	0	0		1	1	(4.3%)
General disorders and administration site conditions	1	1	(10.0%)	1	1	(7.7%)	2	2	(8.7%)
Disease progression	1	1	(10.0%)	1	1	(7.7%)	2	2	(8.7%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Uncontrolled Treatment Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=10)			rhNGF 20 µg/ml (N=13)			Total (N=23)		
	N*	n	%	N*	n	%	N*	n	%
Investigations	1	1	(10.0%)	1	1	(7.7%)	2	2	(8.7%)
Blood creatinine increased	1	1	(10.0%)	0	0		1	1	(4.3%)
Intraocular pressure increased	0	0		1	1	(7.7%)	1	1	(4.3%)
Immune system disorders	1	1	(10.0%)	0	0		1	1	(4.3%)
Corneal graft rejection	1	1	(10.0%)	0	0		1	1	(4.3%)
Nervous system disorders	0	0		1	1	(7.7%)	1	1	(4.3%)
Headache	0	0		1	1	(7.7%)	1	1	(4.3%)
Renal and urinary disorders	1	1	(10.0%)	0	0		1	1	(4.3%)
Renal colic	1	1	(10.0%)	0	0		1	1	(4.3%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Any Adverse Events	75	22	(35.5%)	51	17	(26.2%)	15	9	(31.0%)	141	48	(30.8%)
Eye disorders	28	14	(22.6%)	21	11	(16.9%)	9	6	(20.7%)	58	31	(19.9%)
Blepharitis	1	1	(1.6%)	2	2	(3.1%)	2	2	(6.9%)	5	5	(3.2%)
Corneal epithelium defect	0	0		5	5	(7.7%)	0	0		5	5	(3.2%)
Cataract	3	3	(4.8%)	0	0		0	0		3	3	(1.9%)
Corneal erosion	5	2	(3.2%)	1	1	(1.5%)	0	0		6	3	(1.9%)
Corneal neovascularisation	2	2	(3.2%)	3	1	(1.5%)	0	0		5	3	(1.9%)
Dry eye	1	1	(1.6%)	1	1	(1.5%)	1	1	(3.4%)	3	3	(1.9%)
Neurotrophic keratopathy	3	2	(3.2%)	1	1	(1.5%)	0	0		4	3	(1.9%)
Ulcerative keratitis	3	3	(4.8%)	0	0		0	0		3	3	(1.9%)
Conjunctival haemorrhage	2	2	(3.2%)	0	0		0	0		2	2	(1.3%)
Conjunctivitis	1	1	(1.6%)	1	1	(1.5%)	0	0		2	2	(1.3%)
Eye pain	0	0		1	1	(1.5%)	1	1	(3.4%)	2	2	(1.3%)
Keratitis	0	0		4	2	(3.1%)	0	0		4	2	(1.3%)
Lacrimation decreased	1	1	(1.6%)	1	1	(1.5%)	0	0		2	2	(1.3%)
Corneal opacity	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Eyelid pain	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Eye disorders												
Foreign body sensation in eyes	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Lacrimation increased	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Lenticular opacities	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Meibomianitis	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Ocular discomfort	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Ocular hyperaemia	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Pseudopterygium	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Retinal cyst	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Vitreous haemorrhage	2	1	(1.6%)	0	0		0	0		2	1	(0.6%)
Infections and infestations	12	8	(12.9%)	9	6	(9.2%)	2	2	(6.9%)	23	16	(10.3%)
Nasopharyngitis	3	3	(4.8%)	1	1	(1.5%)	1	1	(3.4%)	5	5	(3.2%)
Helicobacter gastritis	2	2	(3.2%)	0	0		0	0		2	2	(1.3%)
Herpes ophthalmic	2	2	(3.2%)	0	0		0	0		2	2	(1.3%)
Keratitis herpetic	0	0		2	2	(3.1%)	0	0		2	2	(1.3%)
Blister infected	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Catheter site infection	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Infections and infestations												
Corneal abscess	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Corneal infection	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Cystitis	0	0		2	1	(1.5%)	0	0		2	1	(0.6%)
Herpes simplex ophthalmic	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Herpes zoster ophthalmic	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Onychomycosis	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Sinusitis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Tonsillitis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Urinary tract infection	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Injury, poisoning and procedural complications	3	3	(4.8%)	2	1	(1.5%)	3	2	(6.9%)	8	6	(3.8%)
Clavicle fracture	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Facial bones fracture	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Fall	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Femur fracture	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Pelvic fracture	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Tibia fracture	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Injury, poisoning and procedural complications												
Transplant failure	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Upper limb fracture	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Investigations	3	3	(4.8%)	3	3	(4.6%)	0	0		6	6	(3.8%)
Intraocular pressure increased	1	1	(1.6%)	2	2	(3.1%)	0	0		3	3	(1.9%)
Blood pressure increased	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Heart rate increased	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Vital dye staining cornea present	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
General disorders and administration site conditions	3	2	(3.2%)	5	3	(4.6%)	0	0		8	5	(3.2%)
Disease progression	1	1	(1.6%)	3	1	(1.5%)	0	0		4	2	(1.3%)
Inflammation	1	1	(1.6%)	1	1	(1.5%)	0	0		2	2	(1.3%)
Impaired healing	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Instillation site pain	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Vascular disorders	7	5	(8.1%)	0	0		0	0		7	5	(3.2%)
Aortic dissection	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Aortic rupture	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Deep vein thrombosis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Diabetic vascular disorder	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Diastolic hypotension	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Hypertension	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Shock haemorrhagic	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Gastrointestinal disorders	3	3	(4.8%)	1	1	(1.5%)	0	0		4	4	(2.6%)
Abdominal pain upper	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Diverticular perforation	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Gastric polyps	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Nausea	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Metabolism and nutrition disorders	3	2	(3.2%)	2	2	(3.1%)	0	0		5	4	(2.6%)
Decreased appetite	2	1	(1.6%)	0	0		0	0		2	1	(0.6%)
Hyperuricaemia	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Hypokalaemia	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Metabolism and nutrition disorders												
Vitamin D deficiency	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Respiratory, thoracic and mediastinal disorders	2	2	(3.2%)	1	1	(1.5%)	1	1	(3.4%)	4	4	(2.6%)
Respiratory failure	0	0		1	1	(1.5%)	1	1	(3.4%)	2	2	(1.3%)
Dyspnoea	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Epistaxis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Cardiac disorders	3	3	(4.8%)	0	0		0	0		3	3	(1.9%)
Arrhythmia	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Cardiac failure	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Myocardial infarction	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Nervous system disorders	1	1	(1.6%)	2	2	(3.1%)	0	0		3	3	(1.9%)
Burning sensation	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Headache	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Syncope	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Immune system disorders	0	0		3	2	(3.1%)	0	0		3	2	(1.3%)
Corneal graft rejection	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Immunodeficiency	0	0		2	1	(1.5%)	0	0		2	1	(0.6%)
Renal and urinary disorders	1	1	(1.6%)	1	1	(1.5%)	0	0		2	2	(1.3%)
Bladder prolapse	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Renal colic	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Blood and lymphatic system disorders	3	1	(1.6%)	0	0		0	0		3	1	(0.6%)
Anaemia	3	1	(1.6%)	0	0		0	0		3	1	(0.6%)
Hepatobiliary disorders	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Cholelithiasis	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Musculoskeletal and connective tissue disorders	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Intervertebral disc protrusion	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42

Table 14.3.1.2b Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Reproductive system and breast disorders	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Uterine prolapse	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Skin and subcutaneous tissue disorders	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Diabetic foot	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.
Top N counts relate to the number of patients who have received each treatment in the specified study period. Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in the Vehicle Control group in the Controlled Treatment Period and their Uncontrolled Treatment group in the Uncontrolled Treatment Period and Follow-Up Period.
Percentages are calculated using the population number in each treatment group (N) as the denominator.
Body system and preferred terms are sorted by descending frequency of patient count in the Total column.
Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.
The data presented in this Table are contained in Listing 16.2.7.1b

Program path: \Dompe\rhNGF\NGF0212\Stat\programs\tables\rtae.sas Executed: 16OCT2015, 09:42